Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.Federica Miglietta, Maria Vittoria Dieci, Matilde Cacciatore et al.|Journal of Clinical Oncology|2024Cited by 1
Abstract PS14-05: Clinically actionable genomic alterations in breast cancer brain metastasesGaia Griguolo, Valentina Guarneri, Antonio Collesei et al.|Clinical Cancer Research|2025Cited by 0